Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/11/2017
SIETES contiene 92130 citas

 
 
 1 a 20 de 37 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Woloshin S, Schwartz LM, White B, Moore TJ. The fate of FDA postapproval studies. N Engl J Med 2017;377:1114-7. [Ref.ID 102072]
4. Cita con resumen
Huang Z, Ma J. Chronic purulent nasal discharge. BMJ 2017;357:j2061. [Ref.ID 101636]
5. Cita con resumen
Downing NS, Shah ND, Aminawung JA, Pease AM, Zeitoun JD, Krumholz HM, Ross JS. Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010. JAMA 2017;317:1854-63. [Ref.ID 101567]
6. Cita con resumen
Schick A, Miller KL, Lanthier M, Pan GD, Nardinelli C. Evaluation of pre-marketing factors to predict post-marketing boxed warnings and safety withdrawals. Drug Saf 2017:24 de marzo. [Ref.ID 101505]
8. Cita con resumen
Anónimo. FDA grants priority review to Novartis’ leukemia drug. DIA Daily 2016:2. [Ref.ID 100923]
10. Cita con resumen
Anónimo. FDA grants accelerated approval to olaratumab to treat advanced STS. DIA Daily 2016:2. [Ref.ID 100834]
11. Cita con resumen
Anónimo. FDA accepts NDA for valbenazine, grants priority review. DIA Daily 2016:4. [Ref.ID 100806]
13. Cita con resumen
Anónimo. FDA grants Biogen fast-track designation for Alzheimer’s drug. Kaiser Health News 2016:1. [Ref.ID 100625]
14.Tiene citas relacionadas Cita con resumen
Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med 2016;375:65-74. [Ref.ID 100614]
15.Tiene citas relacionadas Cita con resumen
Davis C, Lexchin J, Jefferson T, Gotzsche P, McKee M. "Adaptive pathways” to drug authorisation: adapting to industry?. BMJ 2016;354:i4437. [Ref.ID 100602]
16.Tiene citas relacionadas Cita con resumen
Hawkes N. German body calls for pause in European plan for fast track drug approval. BMJ 2016;354:i4479. [Ref.ID 100601]
17. Cita con resumen
Anónimo. FDA grants expedited review to ovarian cancer drug. DIA Daily 2016:2. [Ref.ID 100591]
19. Cita con resumen
Wise J. NICE approves immunotherapy combination for advanced melanoma. BMJ 2016;353:i3421. [Ref.ID 100435]
20. Cita con resumen
Hawkes N. Specialists attack drug agency’s fast track approval scheme. BMJ 2016;353:i3060. [Ref.ID 100382]
Seleccionar todas
 
 1 a 20 de 37 siguiente >>